Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
Journal
The Lancet. Oncology
Journal Volume
23
Journal Issue
6
Pages
781
Date Issued
2022-06
Author(s)
Cho, Byoung Chul
Abreu, Delvys Rodriguez
Hussein, Maen
Cobo, Manuel
Patel, Anjan J
Secen, Nevena
Lee, Ki Hyeong
Massuti, Bartomeu
Hiret, Sandrine
Barlesi, Fabrice
Lee, Dae Ho
Ares, Luis Paz
Hsieh, Robert W
Patil, Namrata S
Twomey, Patrick
Yang, Xiaoying
Meng, Raymond
Johnson, Melissa L
Abstract
Targeted inhibition of the PD-L1-PD-1 pathway might be further amplified through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune checkpoint agents, such as tiragolumab. In the CITYSCAPE trial, we aimed to assess the preliminary efficacy and safety of tiragolumab plus atezolizumab (anti-PD-L1) therapy as first-line treatment for non-small-cell lung cancer (NSCLC).
SDGs
Publisher
ELSEVIER SCIENCE INC
Type
journal article